The US Bankruptcy Court gave an order approving the sale of certain assets of Pear Therapeutics, Inc. on May 23, 2023. The debtor has been authorized to sell its certain assets to Harvest Bio LLC for a purchase price of $2.03 million in cash plus assumption of the assumed liabilities plus any cure costs. The debtorâs assets include Invention Science Fund licenses and patents, schizophrenia (Pear-004), multiple sclerosis and depression (Pear-006), major depressive disorder, other pipeline assets, corporate trademarks, PearConnect, and reSET® and reSET-O®.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | -.--% | -.--% |
Mar. 22 | Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc. | CI |
Mar. 04 | Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 142 | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+48.60% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- PEARQ Stock
- News Pear Therapeutics, Inc.
- Motion for Asset Sale Approved for Pear Therapeutics, Inc.